Photosensitizer-induced HPV16 E7 nanovaccines for cervical cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Biomedical Engineering

Background:

• Advanced cervical cancer lacks effective treatments, highlighting the need for novel therapeutic strategies.
• Therapeutic human papillomavirus (HPV) vaccines represent a promising avenue for cancer treatment.
• Designing efficient and effective therapeutic vaccines remains a significant challenge in oncology.

Purpose of the Study:

• To construct and evaluate a novel nanovaccine for inhibiting cervical cancer progression.
• To combine nanotechnology with photodynamic therapy for enhanced therapeutic efficacy.
• To investigate the nanovaccine's ability to stimulate antitumor immunity.

Main Methods:

• A nanovaccine was engineered by linking bovine serum albumin (BSA) with the E7 antigen.
• Photosensitizer and adjuvant were encapsulated within the BSA-E7 structure via disulfide bonds.
• The nanovaccine's efficacy was assessed in a TC-1 cervical cancer mouse model (C57BL/6 mice).
• Infrared laser irradiation was used to activate the photosensitizer, inducing a photo-oxygen response.

Main Results:

• The nanovaccine demonstrated high biocompatibility and structural stability.
• Slow-release properties and targeted lymph node delivery were observed.
• The nanovaccine effectively induced dendritic cell maturation and T cell responses.
• Significant inhibition of tumor progression was achieved in the experimental model.

Conclusions:

• The developed HPV nanovaccine effectively inhibits cervical cancer progression.
• This strategy enhances antitumor immunity through induced immune cell maturation and T cell activation.
• The approach holds potential for future clinical applications in therapeutic HPV vaccines.